MarketScreener

Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)

Global Phase 2b/3 Study Will Evaluate Symptom Duration and Hospitalization Rates in Adult Outpatients at High Risk of Severe Outcomes from RSV Topline Phase 2b Data Expected in 2027 Enanta ...

Group homes to be subject to volume control from April 2027. After checking 139 designated authorities nationwide, only 28 are currently regulating, and only 3 had …

Update HistoryOctober 26, 2026: First edition (139 designated authorities nationwide checked on October 26, 2026)When opening ...

A new scientific avenue for daridorexant: Idorsia to advance development in autism spectrum disorder

Ad hoc announcement pursuant to Art. 53 LR In a Phase 2 study in pediatric insomnia disorder, in addition to marked ...